Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Merck & Co, Inc.

Medical Crossfire®: Evidence-Based Care for Head and Neck Squamous Cell Cancer: Practical Application of Recent Data Sets to Optimize Patient Outcomes

Release Date: October 30, 2020
Expiration Date: October 30, 2021

Activity Overview

The Medical Crossfire®, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirited discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the latest data regarding current and emerging therapeutic strategies, including immune checkpoint inhibition, for the management of head and neck squamous cell carcinoma (HNSCC). This lively discussion will help place new developments into clinical context in order to help optimize care for patients with HNSCC.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Merck & Co, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical, radiation, and surgical oncologists interested in the diagnosis and treatment of head and neck squamous cell carcinoma (HNSCC). Fellows, nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with HNSCC are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Recognize the predictive and prognostic value of biomarkers and diagnostic tests approved in the HNSCC setting
  • Discuss current and emerging safety and efficacy data and recent clinical advances of immune checkpoint inhibitor therapy for patients diagnosed with HNSCC
  • Formulate a plan for monitoring and mitigating immune-related adverse events related to checkpoint inhibitor therapy for the treatment of HNSCC
  • Describe the importance of multidisciplinary care and benefits of a multidisciplinary tumor board for the management of HNSCC

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Ezra Cohen, MD, FRCPSC, FASCO
Ezra Cohen, MD, FRCPSC, FASCO
Chief of Division of Division of Hematology/Oncology, Department of Medicine, UC San Diego
Co-Director, San Diego Center Precision Immunotherapy
Associate Director for Translational Science
Moores Cancer Center
Co-leader, Solid Tumor Therapeutics Program
La Jolla, CA

Disclosures: Consultant: AstraZeneca, Bristol Myers Squibb, Eisai, Merck, Pfizer.

Robert L. Ferris, MD, PhD, FACS
Robert L. Ferris, MD, PhD, FACS
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice Chancellor for Cancer Research
Co-Director, Tumor Microenvironment Center
Professor of Otolaryngology, of Immunology, and of Radiation Oncology
University of Pittsburgh
Pittsburgh, PA

Disclosures: Grant/Research Support: Abbvie; AstraZeneca/MedImmune; Biogen Idec; Bristol Myers Squibb; Castle Biosciences; Eli Lilly; Janssen; Merck; Novartis; Novasenta; Regeneron; Tesaro. Consultant: Aduro Biotech, Inc; Bristol Myers Squibb; DermTech; Eli Lilly; EMD Serono; Janssen; MacroGenics, Inc.; Merck; Novasenta; Numab Therapeutics AG; Pfizer; Tesaro. Stock/ Shareholder: Novasenta.

Andrew B. Sharabi, MD, PhD
Andrew B. Sharabi, MD, PhD
Assistant Professor of Radiation Medicine and Applied Sciences
Director, Radiation Medicine Core Facility
Moores Cancer Center
UC San Diego
La Jolla, CA

Disclosures: Grant/Research Support: Varian Medical Systems; Pfizer. Consultant: AstraZeneca; Jounce Therapeutics; Merck. Stock/ Shareholder: Toragen Inc.

Trisha M. Wise-Draper, MD, PhD
Trisha M. Wise-Draper, MD, PhD
Medical Director of UCCC Clinical Trials Office
University of Cincinnati Cancer Center
Associate Professor of Medicine
Division of Hematology/Oncology, Head and Neck Cancer, Experimental Therapeutics
University of Cincinnati
Cincinnati, OH

Disclosures: Grant/Research Support: Bristol Myers Squibb; GSK/Tesaro; Merck; Consultant: Exicure; Rakuten Medical; Shattuck Labs.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By